Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19.
Keywords: SARS-CoV-2; covid-19; psoriasis; biologic; therapies.
This article is protected by copyright. All rights reserved.
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.J Eur Acad Dermatol Venereol. 2020 Apr 15. doi: 10.1111/jdv.16468. Online ahead of print. J Eur Acad Dermatol Venereol. 2020. PMID: 32294258
Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.Endocr Metab Immune Disord Drug Targets. 2020 Apr 27. doi: 10.2174/1871530320666200427112902. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 32338224
Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.Dermatol Ther (Heidelb). 2020 Apr 16:1-11. doi: 10.1007/s13555-020-00377-9. Online ahead of print. Dermatol Ther (Heidelb). 2020. PMID: 32300516 Free PMC article.
Features, Evaluation and Treatment Coronavirus (COVID-19).2020 Apr 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 32150360 Free Books & Documents. Review.
Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice.J Eur Acad Dermatol Venereol. 2020 Apr 22. doi: 10.1111/jdv.16515. Online ahead of print. J Eur Acad Dermatol Venereol. 2020. PMID: 32320091 Review.